Frankincense myrrh attenuates hepatocellular carcinoma by regulating tumor blood vessel development through multiple epidermal growth factor receptor-mediated signaling pathways

doi:10.4251/wjgo.v14.i2.450

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 2

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6141)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-11) series, Tables (1-3) series.

Item

Count

PDF

329

WORD

125

HTML

3416

Figures (1-11)

324

Tables (1-3)

299

Sum=4493

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

268

Download

442

Sum=710

Publishing Process of This Article

Item

Count

Browse

268

Download

670

Sum=938

Feb 15, 2022 (publication date) through Jun 30, 2024

Times Cited of This Article

Times Cited (10)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Gastrointest Oncol. Feb 15, 2022; 14(2): 450-477
Published online Feb 15, 2022. doi: 10.4251/wjgo.v14.i2.450

Full Size Figure Download Figure

Figure 11 Schematic of frankincense and myrrh as potential anti hepatocellular carcinoma therapeutic agents.

Citation: Zheng P, Huang Z, Tong DC, Zhou Q, Tian S, Chen BW, Ning DM, Guo YM, Zhu WH, Long Y, Xiao W, Deng Z, Lei YC, Tian XF. Frankincense myrrh attenuates hepatocellular carcinoma by regulating tumor blood vessel development through multiple epidermal growth factor receptor-mediated signaling pathways. World J Gastrointest Oncol 2022; 14(2): 450-477
URL: https://www.wjgnet.com/1948-5204/full/v14/i2/450.htm
DOI: https://dx.doi.org/10.4251/wjgo.v14.i2.450